BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 11981013)

  • 1. Clinical relevance of MGMT in the treatment of cancer.
    Gerson SL
    J Clin Oncol; 2002 May; 20(9):2388-99. PubMed ID: 11981013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
    Liu L; Schwartz S; Davis BM; Gerson SL
    Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
    Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.
    Phillips WP; Willson JK; Markowitz SD; Zborowska E; Zaidi NH; Liu L; Gordon NH; Gerson SL
    Cancer Res; 1997 Nov; 57(21):4817-23. PubMed ID: 9354444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
    Spiro T; Liu L; Gerson S
    Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.
    Cai Y; Wu MH; Xu-Welliver M; Pegg AE; Ludeman SM; Dolan ME
    Cancer Res; 2000 Oct; 60(19):5464-9. PubMed ID: 11034089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy.
    Davis BM; Roth JC; Liu L; Xu-Welliver M; Pegg AE; Gerson SL
    Hum Gene Ther; 1999 Nov; 10(17):2769-78. PubMed ID: 10584923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.
    Liu L; Markowitz S; Gerson SL
    Cancer Res; 1996 Dec; 56(23):5375-9. PubMed ID: 8968088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Davis BM; Reese JS; Koç ON; Lee K; Schupp JE; Gerson SL
    Cancer Res; 1997 Nov; 57(22):5093-9. PubMed ID: 9371508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. G156A MGMT-transduced human mesenchymal stem cells can be selectively enriched by O6-benzylguanine and BCNU.
    Lee K; Gerson SL; Maitra B; Koç ON
    J Hematother Stem Cell Res; 2001 Oct; 10(5):691-701. PubMed ID: 11672516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system.
    Alvino E; Castiglia D; Caporali S; Pepponi R; Caporaso P; Lacal PM; Marra G; Fischer F; Zambruno G; Bonmassar E; Jiricny J; D'Atri S
    Int J Oncol; 2006 Oct; 29(4):785-97. PubMed ID: 16964376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells.
    Ragg S; Xu-Welliver M; Bailey J; D'Souza M; Cooper R; Chandra S; Seshadri R; Pegg AE; Williams DA
    Cancer Res; 2000 Sep; 60(18):5187-95. PubMed ID: 11016647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation of human O6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine.
    Xu-Welliver M; Kanugula S; Pegg AE
    Cancer Res; 1998 May; 58(9):1936-45. PubMed ID: 9581836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy.
    Rabik CA; Njoku MC; Dolan ME
    Cancer Treat Rev; 2006 Jun; 32(4):261-76. PubMed ID: 16698182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of the conserved residue tyrosine-158 to histidine renders human O6-alkylguanine-DNA alkyltransferase insensitive to the inhibitor O6-benzylguanine.
    Xu-Welliver M; Leitão J; Kanugula S; Pegg AE
    Cancer Res; 1999 Apr; 59(7):1514-9. PubMed ID: 10197622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.
    Sabharwal A; Middleton MR
    Curr Opin Pharmacol; 2006 Aug; 6(4):355-63. PubMed ID: 16777483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential sensitivity of human and mouse alkyltransferase to O6-benzylguanine using a transgenic model.
    Liu L; Lee K; Wasan E; Gerson SL
    Cancer Res; 1996 Apr; 56(8):1880-5. PubMed ID: 8620508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conserved residue lysine165 is essential for the ability of O6-alkylguanine-DNA alkyltransferase to react with O6-benzylguanine.
    Xu-Welliver M; Kanugula S; Loktionova NA; Crone TM; Pegg AE
    Biochem J; 2000 Apr; 347(Pt 2):527-34. PubMed ID: 10749683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Point mutations in human O6-alkylguanine-DNA alkyltransferase prevent the sensitization by O6-benzylguanine to killing by N,N'-bis (2-chloroethyl)-N-nitrosourea.
    Loktionova NA; Pegg AE
    Cancer Res; 1996 Apr; 56(7):1578-83. PubMed ID: 8603405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.
    Koç ON; Reese JS; Davis BM; Liu L; Majczenko KJ; Gerson SL
    Hum Gene Ther; 1999 Apr; 10(6):1021-30. PubMed ID: 10223735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.